Clene, Inc.’s CNM-Au8 for amyotrophic lateral sclerosis has missed the mark in a Phase II/III trial but positive data in a secondary survival endpoint could help pave the way to market, given recent approvals in the space.
The investigator-initiated Healey ALS Platform trial randomized 161 patients to 30mg or 60mg CNM-Au8 or placebo with standard of care...